IP Verse

Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient

EP2395968

BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Application Number
EP10703652A
Filing Date
Feb 11, 2010
Status
Granted And Under Opposition
Dec 15, 2023
Grant Date
Jan 17, 2024
External Links
Slate, Register

Biblio Summary

The patent EP2395968B1 was granted on Jan 17, 2024 by Boehringer Ingelheim International Gmbh The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 18 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRAND MURRAY FULLER LLPOct 17, 2024ADMISSIBLE
BRAND MURRAY FULLER SERVICES LIMITEDOct 17, 2024ADMISSIBLE
GENERICS (UK) LTDOct 17, 2024ADMISSIBLE
HGF LIMITEDOct 17, 2024ADMISSIBLE
LUIGI, RUMIOct 17, 2024ADMISSIBLE
MAIWALD GMBHOct 17, 2024ADMISSIBLE
STADA ARZNEIMITTEL AGOct 17, 2024ADMISSIBLE
ZBM PATENTS, S.L.Oct 17, 2024ADMISSIBLE
AERA A/SOct 16, 2024ADMISSIBLE
GALENICUM HEALTH S.L.U.Oct 16, 2024ADMISSIBLE
HAMM&WITTKOPP PATENTANWALTE PARTMBBOct 16, 2024ADMISSIBLE
KRAUS & LEDERER PARTGMBBOct 16, 2024ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIES, LTD.Oct 16, 2024ADMISSIBLE
BULLE DR., JANOct 15, 2024ADMISSIBLE
CAMULON LIMITEDOct 14, 2024ADMISSIBLE
ZENTIVA K.S.Oct 14, 2024ADMISSIBLE
SANDOZ AGOct 10, 2024ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Oct 10, 2024ADMISSIBLE

More Opposed Patents of Boehringer Ingelheim International Gmbh

The table below shows the patents of Boehringer Ingelheim International Gmbh that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2313087Pharmaceutical Dosage Form For Immediate Release Of An Indolinone DerivativeNov 22, 20233
EP3110449Medical Use Of A Dpp-4 InhibitorJun 28, 20235
EP3802922Novel Immune Checkpoint InhibitorsApr 26, 20231

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents